remnant-cholesterol
(2)
Marea Therapeutics
Marea Therapeutics is a clinical-stage biotechnology company in San Francisco developing first-in-class medicines for cardioendocrine and cardiometabolic diseases. Incubated by Third Rock Ventures and led by Dr. Josh Lehrer, Marea uses human genetics insights to drive its pipeline, headlined by MAR001, an ANGPTL4-targeting antibody aimed at residual cardiovascular risk, and MAR002 for acromegaly.
Josh Lehrer
Josh Lehrer is a physician-scientist and biotech executive serving as CEO of Marea Therapeutics, a clinical-stage company harnessing human genetics to develop first-in-class medicines for cardiometabolic diseases. A cardiologist by training with degrees from Harvard, Cambridge, and UCSF, Lehrer brings over two decades of drug development experience spanning Genentech, Global Blood Therapeutics (where he oversaw the FDA approval of Oxbryta for sickle cell disease), and Graphite Bio. At Marea, he has led the company from a Third Rock Ventures incubation to a $190 million-funded enterprise with two clinical-stage programs showing strong early efficacy data, including a 53% reduction in remnant cholesterol with MAR001 published in The Lancet.